Supriya Lifescience Limited

NSE: SUPRIYA · Healthcare

₹695.80-19.99%06 Nov 2026

Ask the data

Instant answers about Supriya Lifescience Limited — computed from its filings, no language model

Market cap₹5,600 cr

Current price₹695.80

High / Low₹1,052 / ₹553

P/E31.6

P/B4.51

Book value₹154.4

ROE14.3%

ROCE19.3%

Debt / equity0.00

Dividend yield0.14%

EPS (TTM)₹22.02

Face value₹2

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

	FY22	FY23	FY24	FY25	FY26
Revenue	530.0	460.9	570.4	696.5	827.9
EBITDA	214.0	128.9	173.0	260.8	294.1
Operating margin	40.4%	28.0%	30.3%	37.4%	35.5%
Interest	4.2	3.1	2.1	1.7	1.9
Depreciation	10.1	11.8	15.8	20.4	28.4
Profit before tax	207.2	123.5	165.7	248.5	274.8
Tax	55.4	33.6	46.6	60.5	65.7
Net profit	151.8	89.9	119.1	188.0	209.1
EPS ₹	18.86	11.16	14.80	23.35	25.98
Operating cash flow	48.8	66.2	113.3	164.7	185.8
Capex	59.9	108.4	145.7	162.4	152.2
Dividend paid	4.4	4.8	4.8	6.4	8.1
Total assets	—	820.3	921.2	1,112.3	1,357.1
Equity	—	699.5	815.4	996.8	1,197.7

Quarterly performance

last 20 quarters · ₹ crore

showing latest 8 of 20 periods

	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	117.0	181.3	101.4	112.2	105.1	142.3	132.0	140.1	140.1	158.2	160.6	166.1	185.7	184.1	145.1	199.8	206.4	276.5	189.8	206.3
Operating profit	38.4	75.2	31.2	28.6	14.0	55.0	44.5	31.8	41.5	55.5	62.5	64.7	66.0	67.6	51.7	72.7	72.1	97.6	47.5	45.4
Operating margin	32.8%	41.5%	30.8%	25.5%	13.4%	38.7%	33.7%	22.7%	29.6%	35.1%	38.9%	39.0%	35.5%	36.7%	35.6%	36.4%	34.9%	35.3%	25.0%	22.0%
Other income	5.4	3.9	2.4	2.6	2.6	2.0	2.9	2.5	3.1	2.2	2.2	2.5	2.1	3.0	2.7	2.7	2.6	3.5	2.6	2.3
Interest	1.1	1.0	0.6	0.8	1.0	0.7	0.8	0.5	0.5	0.6	0.3	0.4	0.5	0.4	0.5	0.4	0.5	0.5	0.4	0.5
Depreciation	2.6	2.6	2.9	3.0	3.0	3.0	4.0	4.0	4.0	3.9	4.7	4.7	5.0	6.1	6.5	6.6	6.8	8.5	8.9	9.5
Profit before tax	40.1	75.5	30.1	27.4	12.6	53.3	42.6	29.8	40.1	53.2	59.8	62.1	62.6	64.1	47.4	68.3	66.9	92.1	40.8	37.8
Tax	0.4	29.3	4.9	10.6	3.1	15.1	14.1	5.9	10.3	16.2	15.1	15.9	15.8	13.7	12.6	17.9	17.2	17.9	16.8	8.5
Net profit	39.6	46.2	25.2	16.9	9.5	38.2	28.5	23.9	29.8	36.9	44.6	46.1	46.8	50.4	34.8	50.4	49.7	74.2	24.0	29.2
EPS ₹	4.93	5.74	3.14	2.10	1.18	4.75	3.54	2.97	3.70	4.59	5.54	5.71	5.82	6.29	4.32	6.27	6.17	9.22	2.99	3.63
Revenue YoY	—	—	—	—	-10.1%	-21.5%	30.2%	24.9%	33.2%	11.2%	21.7%	18.6%	32.5%	16.4%	-9.7%	20.3%	11.2%	50.2%	30.8%	3.2%
Profit YoY	—	—	—	—	-76.0%	-17.3%	12.9%	41.6%	212.9%	-3.4%	56.6%	93.3%	57.0%	36.4%	-22.1%	9.3%	6.2%	47.3%	-30.9%	-42.0%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 17 periods

	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	19.6%	15.0%	12.8%	13.3%	13.3%	16.0%	14.6%	16.6%	17.4%	19.3%	18.9%	17.9%	16.9%	17.1%	17.5%	16.6%	14.3%
ROCE	25.9%	21.8%	17.7%	19.5%	18.8%	22.3%	20.6%	22.7%	23.9%	26.4%	25.1%	23.9%	22.6%	23.0%	23.1%	22.5%	19.3%
Net margin	25.0%	19.6%	19.5%	18.9%	19.3%	21.7%	20.9%	22.6%	25.2%	26.0%	27.0%	26.2%	25.5%	25.2%	25.3%	22.7%	20.2%
EBITDA margin	33.9%	29.8%	28.0%	28.9%	28.0%	31.2%	30.4%	31.9%	35.9%	37.1%	37.4%	36.7%	36.1%	35.9%	35.5%	33.2%	29.9%
Debt / equity	0.05	0.05	0.02	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest coverage	50.04	43.97	41.09	41.96	47.12	67.86	70.91	97.73	116.65	127.37	147.16	127.26	132.01	135.81	147.16	155.11	133.75
Asset turnover	0.67	0.66	0.56	0.60	0.62	0.66	0.62	0.65	0.62	0.66	0.63	0.61	0.59	0.61	0.61	0.64	0.62

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 9 periods

	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	16.1	16.1	16.1	16.1	16.1	16.1	16.1	16.1	16.1
Other equity / reserves	635.9	683.4	737.1	799.3	889.8	980.7	1,065.7	1,181.6	1,226.5
Total equity	652.0	699.5	753.2	815.4	905.9	996.8	1,081.8	1,197.7	1,242.6
Borrowings	30.4	16.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Current liabilities	88.6	95.8	65.6	76.9	75.4	82.2	82.9	121.0	130.4
Non-current liabilities	21.2	25.0	24.3	29.0	31.1	33.4	38.3	38.3	48.6
Total assets	761.8	820.3	843.0	921.2	1,012.4	1,112.3	1,203.0	1,357.1	1,421.7
Property, plant & equipment	182.1	255.1	251.5	303.7	300.3	451.5	456.3	683.3	733.4
Capital work-in-progress	74.4	67.6	116.5	148.8	217.5	148.0	172.5	35.5	7.1
Investments	0.1	25.3	57.0	63.8	72.5	63.2	56.5	98.5	106.6
Inventories	106.3	115.8	98.8	85.2	108.0	118.3	142.8	159.6	265.2
Receivables	80.7	84.7	84.8	111.7	105.7	134.4	155.1	219.4	125.6
Cash & equivalents	128.8	85.2	104.0	68.3	77.5	76.1	99.3	37.5	41.0

Cash flow

annual · ₹ crore · line = free cash flow

	FY22	FY23	FY24	FY25	FY26
Cash from operations	48.8	66.2	113.3	164.7	185.8
Cash from investing	-59.8	-133.1	-173.6	-152.2	-176.2
Cash from financing	149.7	-3.4	-22.4	-8.2	-9.9
Capex	59.9	108.4	145.7	162.4	152.2
Free cash flow	-11.1	-42.2	-32.4	2.3	33.5
Dividends paid	4.4	4.8	4.8	6.4	8.1

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹733.4 cr52%

CWIP

₹7.1 cr1%

Investments

₹106.6 cr8%

Inventories

₹265.2 cr19%

Receivables

₹125.6 cr9%

Cash & equivalents

₹41.0 cr3%

Other assets

₹142.7 cr10%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Supriya Lifescience Limited	5,600	695.80	31.6	4.51	14.3%

StoxGud checklist: Neutral setup · 5/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-21.8%

6 months-0.7%

1 year-6.9%

3Y CAGR+39.9%

5Y CAGR—

10Y CAGR—

50-day avg₹876.74

200-day avg₹787.38

RSI (14)24

FAQs

What is the share price of Supriya Lifescience Limited?

Supriya Lifescience Limited (SUPRIYA) closed at ₹695.80 on NSE on 06 Nov 2026.

What is the market cap of Supriya Lifescience Limited?

₹5,600 crore at the latest close.

What is the P/E ratio of Supriya Lifescience Limited?

31.6, on trailing-twelve-month earnings from its filings.

How fast is Supriya Lifescience Limited growing?

Supriya Lifescience Limited: revenue has compounded at 21.6% a year over three years; net profit at 32.5% a year. Latest-quarter revenue is up 3.2% year on year, profit down 42.0%.

How profitable is Supriya Lifescience Limited?

On a trailing-twelve-month basis return on equity is 14.3%, return on capital employed 19.3%, operating margin 29.9%, net margin 20.2%.

How much debt does Supriya Lifescience Limited have?

Supriya Lifescience Limited is debt-free: debt to equity is 0.00 with borrowings of ₹0 cr against cash of ₹41 cr (balance sheet of 2026-09-30). Operating profit covers interest 133.7 times.

Financials parsed from Supriya Lifescience Limited's own XBRL filings to NSE (standalone), ₹ crore unless marked. Quarterly from DEC '21, annual from FY22, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.